De Vita, along with Stephen Maisto, research professor and professor emeritus of psychology, were uniquely prepared to answer that exact question. The pair, along with fellow lab member and doctoral candidate Dezarie Moskal, previously conducted the first systematic review and meta-analysis of experimental research examining the effects cannabinoid drugs on pain.
As the first experimental pain trial to examine CBD, their study yielded consistent and noteworthy results. Among other findings, the data showed that CBD and expectancies for receiving CBD do not appear to reduce experimental pain intensity, but do make the pain feel less unpleasant.
De Vita and Maisto used sophisticated equipment that safely induces experimental heat pain, allowing them to measure how the recipient’s nervous system reacts and responds to it. “Then we administer a drug, like pure CBD, or a placebo and then re-assess their pain responses and see how they change based on which substance was administered,” says De Vita.
Researchers then took it a step further by manipulating the information given to participants about which substances they received. In some cases, participants were told that they got CBD when they actually received a placebo, or told they would be getting a placebo when they actually got CBD.
“That way we could parse out whether it was the drug that relieved the pain, or whether it was the expectation that they had received the drug that reduced their pain,” according to De Vita. “We hypothesized that we would primarily detect expectancy-induced placebo analgesia (pain relief). What we found though after measuring several different pain outcomes is that it’s actually a little bit of both. That is, we found improvements in pain measures caused by the pharmacological effects of CBD and the psychological effects of just expecting that they had gotten CBD. It was pretty remarkable and surprising.”
“The data is exciting but pretty complex in that different pain measures responded differently to the drug effect, to the expectancy, or both the drug and expectancy combined — so we’re still trying to figure out what is behind the differential data with different kinds of pain measures,” said Maisto. “The next step is studying the mechanisms underlying these findings and figuring out why giving instructions or CBD itself causes certain reactions to a pain stimulus.”
Results from his previous study showed that while cannabinoid drugs weren’t reducing the volume of pain, they were “changing the channel making it a little less unpleasant.” According to De Vita, “It’s not sunshine and rainbows pleasant, but something slightly less bothersome. We replicated that in this study and found that CBD and expectancies didn’t significantly reduce the volume of the pain, but they did make it less unpleasant — it didn’t bother them as much.”
As part of the study De Vita and Maisto developed advanced experimental pain measurement protocols “to pop the hood and start looking at some of these other mechanistic pain processes,” says De Vita. “It’s not just pain, yes or no, but there are these other dimensions of pain, and it would be interesting to see which ones are being targeted. We found that sometimes pharmacological effects of CBD brought down some of those, but the expectancies did not. Sometimes they both did it. Sometimes it was just the expectancy. And so, we were going into this thinking we were going to primarily detect the expectancy-induced pain relief but what we found out was way more complex than that and that’s exciting.”
One important note to also consider is the source of the CBD. “What we used in our study was pure CBD isolate oil,” says De Vita. “Commercially available CBD products differ in their content and purity, so results might be different for different CBD products, depending on what other compounds they may or may not contain.”
Journal Reference: Martin J. De Vita, Stephen A. Maisto, Christina E. Gilmour, Lauren McGuire, Elizabeth Tarvin, Dezarie Moskal. The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy adults: A balanced placebo design trial.. Experimental and Clinical Psychopharmacology, 2021; DOI: 10.1037/pha0000465